FDA Panel Endorses Grail's Galleri Blood Test for Cancer Screening
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
An FDA advisory panel has endorsed Galleri, a blood test designed by the biotech firm Grail to screen for multiple types of cancer.
Grail stock was halted Wednesday as a Food and Drug Administration panel discussed the company's blood screening test for cancer.
Grail
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“An FDA advisory panel has endorsed Galleri, a blood test designed by the biotech firm Grail to screen for multiple types of cancer.”
stat news — STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks“Grail stock was halted Wednesday as a Food and Drug Administration panel discussed the company's blood screening test for cancer.”
IBD — The Holy Grail In Cancer? FDA Mulls New Blood Tests.